PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Respiratory Virus Laboratory, Emerging Virus Group, Discovery Biology Department, Institut Pasteur Korea, Seongnam 13488, Gyeonggi, Korea.\', \'Screening Discovery Platform, Translation Research Division, Institut Pasteur Korea, Seongnam 13488, Gyeonggi, Korea.\', \'Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway.\', \'Medicinal Chemistry, Medicinal Chemistry & Business Development Group, Translational Research Department, Institut Pasteur Korea, Seongnam 13488, Gyeonggi, Korea.\', \'Institute of Technology, University of Tartu, 50090 Tartu, Estonia.\', \'Institute for Molecular Medicine Finland, University of Helsinki, 00100 Helsinki, Finland.\', \'Applied Molecular Virology Laboratory, Unmet Medical Needs Group, Discovery Biology Department, Institut Pasteur Korea, Seongnam 13488, Gyeonggi, Korea.\', \'Division of Bio-Medical Science and Technology, University of Science and Technology, Yuseong-gu 305-350, Daejeon, Korea.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 65110.3390/v13040651
?:hasPublicationType
?:journal
  • Viruses
is ?:pmid of
?:pmid
?:pmid
  • 33918958
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.805
?:rankingScore_hIndex
  • 52
is ?:relation_isRelatedTo_publication of
?:title
  • Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all